EventsThe 2nd International Conference on Bioengineering
Published
This submission belongs to event The 2nd International Conference on Bioengineering
Published date
16 Nov, 2026
Contribution&Funding
Conceptualization,
[Claudio Parolo]
Methodology,
[Claudio Parolo]
Formal analysis,
[Claudio Parolo]
Investigation,
[Claudio Parolo]
Resources,
[Claudio Parolo]
Writing - original draft,
[Claudio Parolo]
Writing - review,
[editing] ; [Claudio Parolo]
Supervision,
[Claudio Parolo]
Project administration,
[Claudio Parolo]
Funding acquisition,
[Claudio Parolo]
Funding: --
Citation
Claudio Parolo, From Clinical Need to Commercialization: Building Translational Pathways for Point-of-Care Diagnostics, in Proceedings of The 2nd International Conference on Bioengineering, Barcelona, 10 November–13 November 2026, MDPI: Basel, Switzerland
Share
Email
Facebook
Twitter
LinkedIn

From Clinical Need to Commercialization: Building Translational Pathways for Point-of-Care Diagnostics

1. Chemical Engineering, University Rovira i Virgili, Tarragona, Spain
2. International Health, Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain
3. Global Health Innovative Solutions, Global Health Innovative Solutions, Barcelona, Spain
Abstract

Translating bioengineering research into healthcare impact requires more than demonstrating analytical performance in the laboratory. Technologies must address a clearly defined clinical need, operate under realistic conditions, generate evidence in relevant samples, and ultimately fit within viable pathways for implementation and commercialization. In our work, we follow this translational continuum from clinical need identification to technology development, validation, intellectual property generation, and entrepreneurial exploitation.

Using examples from point-of-care diagnostics for infectious diseases, this talk will illustrate how lateral flow assays, electrochemical biosensors, molecular recognition strategies, and digital readout can be developed around specific clinical questions rather than around technology alone. Imported malaria provides one representative case, where our work has evolved from conventional rapid diagnosis toward quantitative assessment of parasite and host biomarkers associated with disease burden and severity. Related approaches are being extended to other infectious diseases and multiplex diagnostic needs, with increasing emphasis on portable and digitally connected testing.

Beyond assay development, translation also requires consideration of how technologies will reach patients and healthcare systems. I will discuss our experience in protecting diagnostic innovations through intellectual property, creating a spin-off company, and developing FAMBA, a digital health and telemedicine platform designed to connect diagnostic information with remote clinical support. These activities provide a framework for integrating future portable rapid diagnostic tests with digital healthcare services.

The presentation will highlight both the opportunities and the practical challenges encountered when moving from academic bioengineering towards commercialization, and will discuss how clinical partnerships, technology development, validation, intellectual property, digital integration, and entrepreneurship can be combined to build more credible pathways toward real-world diagnostic implementation.

Keywords
Point-of-care diagnostics; Bioinnovation; Translational bioengineering; Rapid diagnostic tests; Digital health; Telemedicine; Technology transfer; Commercialization.
Engineering an Explainable Decision-Support Pipeline for Automated Blood Gas Interpretation
Low-Cost Baropodometric Platform Based on Velostat for Instrumented Evaluation of the Modified Star Excursion Balance Test